News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News February 4, 2026
Advised BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics
Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc.
Client Alert January 27, 2026
False Claims Act 2025 Year-End Update
This update covers recent developments in FCA jurisprudence, summarizes significant enforcement activity, and analyzes the most notable legislative, policy, and …
Client Alert January 22, 2026
Year in Review: Key Legal Developments 2025
We are pleased to share with you a compendium of Gibson Dunn thought leadership on Key Legal Developments in 2025—a year marked by significant change across the legal landscape.
Client Alert January 20, 2026
Supreme Court Holds That State Expert-Affidavit Requirements For Medical Malpractice Claims Do Not Apply In Federal Court
The Supreme Court held that a Delaware statute—requiring that a medical malpractice complaint be accompanied by an expert affidavit—conflicts with the Federal Rules of Civil Procedure and therefore does not apply to suits in federal court.
Client Alert January 12, 2026
HHS and USDA Publish Updated Dietary Guidelines for Americans – What You Need to Know
The new Dietary Guidelines are described by USDA and HHS as marking “the most significant reset of federal nutrition policy in our nation’s history” and include several notable changes from prior editions.
Webcasts October 22, 2025
Webcast: Food and Drug Administration Developments: Key Updates and Compliance
Join our lawyers for a recorded in-depth discussion of recent developments at the U.S. Food and Drug Administration, including the FDA’s crackdown on direct-to-consumer drug advertising and the impact of the Make America Healthy Again initiative, and their implications for the food, drug, device, and cosmetics industries. Our panel of attorneys provide practical insights and strategies for navigating emerging FDA policy, as well as regulatory and enforcement trends.
Firm News October 8, 2025
Gibson Dunn Represents Platinum Equity in Acquisition of Owens & Minor’s Products & Healthcare Services Segment
Gibson Dunn is representing Platinum Equity in its acquisition of the Products & Healthcare Services segment of Owens & Minor.
Client Alert July 30, 2025
FDA and USDA Look to Define “Ultra-Processed Foods”: What You Need to Know
Our lawyers discuss the publishing of a request for information by U.S. Food and Drug Administration and U.S. Department of Agriculture seeking public input on the definition of “ultra-processed foods.”